Search Results

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS) announced today that it has amended certain financial terms of the $20 million convertible note issued by its partner, Cytovia Therapeutics, LLC (“Cytovia”) in payment of the upfront collaboration consideration provided for pursuant to the research collaboration and non-exclusive license agreement between Cellectis and Cytovia.

Cytovia Inc.(DBA Cytovia Therapeutics, Inc.) today announced new preclinical data for its CD38-targeted Flex-NK™ bispecific antibody at the American Society of Hematology’s 64th Annual Meeting (ASH 2022) taking place in New Orleans, LA, and virtually December 10-13th, 2022.

Cytovia Therapeutics, Inc. announced today that its leadership team will present at the following upcoming conferences.

Cytovia Therapeutics, Inc. released the following statement on the passing of Olivier Gouédard, PharmD, MBA, who served as its Chief Operating Officer for the past year.

Isleworth Healthcare Acquisition Corporation (Nasdaq: ISLE)(“Isleworth”), today announced that it has entered into an agreement with Cytovia Holdings, Inc. (“Cytovia”), a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies (the “Termination Agreement”) to terminate its previously announced Merger Agreement with Cytovia

Cytovia Therapeutics, Inc. announced new preclinical data for its TALEN® gene-edited, iPSC-derived NK cells and GPC3-targeted Flex-NK™ bispecific antibodies.

Cytovia Therapeutics, LLC (“Cytovia Therapeutics”), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer.

Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that it will be presenting new preclinical data for its CD38-targeted Flex-NK™ cell engager antibodies at the American Society of Hematology’s 64th Annual Meeting.

Cytovia Therapeutics, LLC announced that Luca Scavo, CPA, MBA has been appointed as Chief Financial Officer and James Priour, MBA has been appointed as Chief Product Officer, both effective immediately.

Cytovia Therapeutics, Inc. announced today that its scientific leadership will present at the following upcoming conferences: iPSC-Derived Cell Therapies Summit (Virtual Event).